obesity drug news today october 2025 glp-1 Agonists Weight Loss Drugs Market Report, 2025-2030 Use of diabetes and anti-obesity
Description
The glucagon-like peptide 1 (GLP-1) market has witnessed robust growth, expanding from $22.06 billion in 2025 to an expected $23.88 billion in 2026, at a compound annual growth rate (CAGR) of 8.2%
References Paccou, J
Future research on dual-receptor agonists may help shed light on their potential benefits in bone health
At least 12 other states cover GLP-1s for obesity treatment
6) Nano-formulations Nano-formulations are advanced drug delivery systems in which active pharmaceutical ingredients (APIs) are formulated at the nanoscale, typically with particle sizes less than 1 m [30, 31]
We are seeing a heavy demand for every part of the peptide as well as the full peptide, says Zibo Cong, the companys marketing manager
